Liver metastases in germ cell cancer: Defining a role for surgery after chemotherapy

BJU International

Volumn 94, Issue 4, 2004, Pages 552-558

  Copson, Ellen ^a   McKendrick, Joe ^b   Hennessey, Niklas ^a   Tung, Ken ^a   Mead, Graham Z ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b BOX HILL HOSPITAL   (Australia)

Author keywords

Chemotherapy; Germ cell cancer; Hepatic metastases; Outcome; Surgery; Survival

Indexed keywords

ANTIINFECTIVE AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINBLASTINE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; GERM CELL TUMOR; HUMAN; LAPAROTOMY; LIVER METASTASIS; LIVER RESECTION; LUNG TOXICITY; MINIMAL RESIDUAL DISEASE; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKULL IRRADIATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BONE NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SEMINOMA; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 4544341907     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04999.x     Document Type: Review

References (31)

1. International Germ Cell Consensus Classification. A prognostic factor based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603
2. Newlands ES, Bagshaw KD, Begent RHJ et al. Current optimum management of anaplastic germ cell tumours of the testis and other sites. Br J Urol 1986; 58: 307-14
3. Stoter G, Sylvester R, Sleijfer DT et al. Multivariate analysis of prognostic factors in patients with disseminated non-seminomatous testicular cancer: Results from an EORTC multi-institutional phase III study. Cancer Res 1987; 47: 2414-8
4. Droz JP, Kramar A, Ghosn M et al. Prognostic factors in advanced non-seminomatous testicular cancer. Cancer 1988; 62: 564-8
5. Birch R, Williams S, Cone A et al. Prognostic factors for favourable outcome in disseminated germ cell tumours. J Clin Oncol 1986; 4: 400-7
6. Mead GM, Stenning SP, Parkinson A et al. The second Medical Research Council study of prognostic factors in non-seminomatous germ cell tumours. Medical Research Council Testicular Tumour Working Party. J Clin Oncol 1992; 10: 85-94
7. COIN Guidelines. Testicular neoplasms. Clin Oncol 2000; 12: S194-7
8. James PB, Mead GM. Sanctuary site relapse in chemotherapy-treated testicular cancer. Ann Oncol 1992; 3: 41-3
9. Stenning SP, Parkinson HC, Fisher C et al. Post-chemotherapy residual masses in germ cell tumour patients. Cancer 1998; 83: 1409-19
10. Murphy BR, Breeden ES, Donohue JP et al. Surgical salvage of chemorefractory germ cell tumours. J Clin Oncol 1993; 11: 324-9
11. Steyerberg EW, Kizer HJ, Fossa SD et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic non-seminomatous germ cell tumour; multivariate analysis of individual patients data from 6 study groups. J Clin Oncol 1995; 13: 1177-87
12. Hahn T, Jacobson L, Einhorn L et al. Hepatic resection of metastatic testicular carcinoma: a further update. Ann Surg Oncol 1999; 6: 640-4
13. Rivoire M, Elias D, De Cian F et al. Multimodality treatment of patients with liver metastases from germ cell tumours. Cancer 2001; 92: 578-87
14. McKendrick JJ, Theaker J, Mead GM. Non-seminomatous germ cell tumour with very high serum human chorionic gonadotrophin. Cancer 1991; 67: 684-9
15. Logothetis CJ. Choriocarcinoma syndrome. The Cancer Bull 1984; 36: 118-20
16. Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumours with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435-40
17. Nichols CR, Catalano PJ, Crawford ED et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumours: An Eastern Co-operative Oncology Group, South East Oncology Group and Cancer and Leukaemia Group B study. J Clin Oncol 1998; 16: 1287-93
18. Culine S, Theodore C, Bekradda M et al. Experience with bleomycin, etoposide (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA)/vinblastine, bleomycin (VBiv) regimens of chemotherapy in poor risk non-seminomatous germ cell tumours. Am J Clin Oncol 1997; 20: 184-8
19. Motzer RJ, Mazumdan M, Bosl GJ et al. High dose carboplatin, etoposide and cyclophosphamide for patients with refractory germ cell tumours: Treatment results and prognostic factors for survival and toxicity. J Clin Oncol 1996; 4: 1098-105
20. Motzer RJ, Mazumdan M, Bajorin D et al. High dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation as first line therapy for patients with poor risk germ cell tumors. J Clin Oncol, 1997; 5: 2546-52
21. Farhat F, Culine S, Theodore C et al. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumours. Cancer 1996; 77: 1193-7
22. Bosyl GI, Geller NL, Bajorin D et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good prognosis germ cell tumours. J Clin Oncol 1988; 6: 1231-8
23. Kaye SB, Mead GM, Fossa S et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic non-seminomatous germ cell tumour: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998; 16: 692-701
24. Saxman S. Salvage therapy in recurrent testicular cancer. Semin Oncol 1992; 19: 143-7
25. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumours. European organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat CI 2000; 92: 205-16
26. Quist HL, Fossa SD, Ous S et al. Post-chemotherapy tumour residuals in patients with advanced non-seminomatous testicular cancer: Is it necessary to resect all residual masses? J Urol 1991; 145: 300-3
27. Meyers WC. Neoplasms of the liver. In Sabiston, DC Jr ed. Textbook of Surgery; the Biological Basis of Modern Surgical Practice. 14th Ed. Philadelphia: WB Saunders 1991: 1008
28. Stephens AW, Gonin R, Hutchins GD, Einhorn L. Positron emission tomography evaluation of residual radiographic abnormalities in post chemotherapy germ cell tumour patients. J Clin Oncol 1996; 14: 1637-41
29. Motzer RJ, Cooper K, Geller NL et al. Carboplatin, etoposide and bleomycin for patients with poor risk germ cell tumours. Cancer 1990; 65: 2465-70
30. Loehrer JP, Cronin R, Nichols CR et al. Vinblastine plus ifosfamide plus cisplatin in initial salvage therapy in recurrent germ cell tumour. J Clin Oncol 1998; 16: 2500-4
31. Jones WG, Stenning SP, Read G et al. Long term follow up of un-resected residual masses following platinum-based chemotherapy for metastatic non-seminoma of the testis (MRC Study TE16). A preliminary report. In Germ Cell Tumours IV. Chichester: John Wiley Co Ltd, 1998: 269-75